After transformation, survival rates varied by original cancer type, with the poorest prognosis for those transformed from CLL/SLL and from LPL/WM.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

THE EUROPEAN Hematology Association-European Medicines Agency (EHA2025-EMA) Joint Symposium on minimal residual disease ...

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, ...

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the ...

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

Real-world data presented at the 2025 International Conference on Malignant Lymphoma (ICML) has provided new insights into the use of clonoSEQ, a circulating tumour DNA (ctDNA) ...

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence ...

The other shoe has dropped for Roche’s bid to move Columvi into earlier treatment of diffuse large B-cell lymphoma (DLBCL) in the U.S. | The other shoe has dropped for Roche’s bid to move ...

Combining duvelisib and romidepsin may provide a path to stem cell transplant for patients with relapsed or refractory peripheral and cutaneous T-cell lymphomas.  Researchers from Somerville, ...